Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Erasca, Inc. (NASDAQ: ERAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage precision oncology issuer. Erasca files current reports on Form 8-K and other documents with the U.S. Securities and Exchange Commission (SEC) that describe financial results, corporate actions, and governance matters.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results for periods ended June 30 and September 30, 2025, where Erasca reported research and development expenses, general and administrative expenses, and net loss figures, along with commentary on its cash, cash equivalents, and marketable securities. Another Form 8-K details the results of the company’s annual meeting of stockholders, including the election of Class I directors and ratification of its independent registered public accounting firm.
For investors analyzing ERAS, these filings complement Erasca’s press releases about its RAS-targeting franchise, including ERAS-0015 and ERAS-4001. While the scientific and clinical details are often highlighted in news announcements, SEC filings provide the formal financial and corporate context, as well as risk factor discussions in periodic reports such as the Form 10-K that the company cites in its cautionary notes.
On Stock Titan, users can review Erasca’s SEC filings as they are made available through EDGAR and use AI-powered summaries to understand key points from lengthy documents, including earnings-related 8-Ks and proxy-related disclosures. This helps readers connect the company’s financial condition and governance decisions with its ongoing efforts to develop therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only webcast at 11:30 a.m. Pacific Time on June 26, 2026. Holders of 310,965,971 shares of common stock as of April 27, 2026 may vote.
Stockholders will elect three Class II directors (Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.) and vote on ratifying KPMG LLP as independent registered public accounting firm for 2026. The proxy also details board governance practices and 2025 executive pay, including CEO Jonathan Lim’s total compensation of $4.3 million and sizable stock option grants.
Erasca, Inc. reported positive preliminary Phase 1 dose escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. Early results come from the AURORAS-1 trial in the United States and the JYP0015M101 trial in China.
The studies enroll patients with colorectal cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, tumor types where KRAS mutations affect an estimated 74,000, 55,000 and 50,000 patients per year in the United States. Erasca has already started ERAS-0015 monotherapy expansion and combination dose escalation cohorts in the United States earlier than its prior guidance.
The company emphasizes that the data are preliminary, include information from a third-party licensor and involve cross-study comparisons that are inherently limited. It highlights multiple development and regulatory risks, including the possibility that future, more complete trial results may differ from current observations.
Erasca, Inc. updated the expected timing for initial Phase 1 monotherapy data from its pan-RAS molecular glue ERAS-0015, now guiding that data from the AURORAS-1 and JYP0015M101 trials will be available no later than mid-May 2026, compared with its prior expectation of the first half of 2026.
AURORAS-1 is evaluating ERAS-0015 in patients with RAS-mutant solid tumors, while licensor Guangzhou Joyo Pharmatech Co., Ltd. is running JYP0015M101 in China in patients with advanced solid tumors harboring specific RAS mutations. The company also highlights typical forward-looking statement risks and directs readers to its risk factor disclosures.
Erasca Foundation reported proposed sales of Common stock in Form 144/A. The filing lists sales dated 01/15/2026, 02/17/2026, and 03/16/2026 with amounts $68,573.87, $99,245.03, and $116,855.46 respectively. The entries are recorded under Erasca Foundation's address in San Diego and identify the securities as Common stock.
Erasca Foundation reported sale transactions of Common stock via Form 144 and lists multiple recent dispositions by the foundation. The filing itemizes dated transfers on 01/15/2026, 02/17/2026, and 03/16/2026 with corresponding amounts shown in the excerpt.
Erasca, Inc. Chief Legal Officer Ebun Garner exercised stock options and sold shares in a planned transaction. On April 1, 2026, Garner exercised options to acquire 80,000 shares of common stock at $1.70 per share, converting a derivative position into common stock.
That same day, Garner sold 80,000 shares of common stock at a weighted-average price of $16.40 per share in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 30, 2024. Following these transactions, Garner directly held 25,076 shares of Erasca common stock.
Erasca, Inc. filed a Form 144 reporting a proposed sale of 80,000 shares of Common Stock associated with a stock option, planned for 04/01/2026 and to be settled for cash. The filing shows an aggregate value of $1,312,354.68 and lists 310,799,547 shares outstanding as of 04/01/2026 as a context figure. The filer also reported a prior sale of 120,000 shares on 01/07/2026 for $670,809.15.
Erasca, Inc. Form 144 filing notifies proposed sales of Common stock by the Erasca Foundation as reported on the form. The filing lists multiple entries with a recurring figure 8333 associated with each sale line and transaction dates such as 02/17/2026, 01/15/2026, and 12/15/2025.
Examples shown include Erasca Foundation entries dated 02/17/2026 (8333) and 01/15/2026 (8333). The filing identifies Nasdaq as the market and includes an apparent reporting date of 03/16/2026.